Restart Life Sciences Corp.
NMLSF
$0.0464
-$0.0066-12.45%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 126.88% | 133.37% | |||
| Depreciation & Amortization | -25.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 128.30% | 132.50% | |||
| Operating Income | -128.30% | -132.50% | |||
| Income Before Tax | -570,600.00% | -99.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -570,600.00% | -99.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -570,600.00% | -99.97% | |||
| EBIT | -128.30% | -132.50% | |||
| EBITDA | -128.55% | -133.37% | |||
| EPS Basic | -- | -100.00% | |||
| Normalized Basic EPS | -32.50% | -122.22% | |||
| EPS Diluted | -280.36% | -138.10% | |||
| Normalized Diluted EPS | -47.22% | -111.76% | |||
| Average Basic Shares Outstanding | 60.31% | 12.42% | |||
| Average Diluted Shares Outstanding | 44.49% | 20.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||